Access cutting-edge head and neck cancer treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.
Access head and neck cancer specialists in New Haven at no cost
This study follows strict safety protocols and ethical guidelines
All study-related head and neck cancer treatment provided free
An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing programmed cell death ligand-1 (PD-L1) with combined positive score (CPS) ≥1. This trial has two parts. Part A, is an initial non-randomized Safety Run-In Phase to confirm the safety and tolerability at the selected dose range level of BNT113
Sponsor: BioNTech SE
Check if you qualify for this head and neck cancer clinical trial in New Haven, CT
If you're searching for head and neck cancer treatment options in New Haven, CT, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced head and neck cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.